143 related articles for article (PubMed ID: 1906778)
21. Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Weaver JR; Wientjes MG; Au JL
Cancer Chemother Pharmacol; 1999; 44(4):335-42. PubMed ID: 10447582
[TBL] [Abstract][Full Text] [Related]
22. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
24. Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay.
Higashihara J; Berens ME; Collins LA; Homesley HD; Welander CE
Gynecol Oncol; 1993 Feb; 48(2):171-9. PubMed ID: 8428687
[TBL] [Abstract][Full Text] [Related]
25. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
[TBL] [Abstract][Full Text] [Related]
26. Enhanced sensitivity to mitomycin C by abating heat shock protein 70 expression in human bladder cancer cell line of BIU-87.
He LF; Guan KP; Yan Z; Ye HY; Xu KX; Ren L; Hou SK
Chin Med J (Engl); 2005 Dec; 118(23):1965-72. PubMed ID: 16336832
[TBL] [Abstract][Full Text] [Related]
27. [Synergistic antitumor effect of sodium caffeate and mitomycin].
Xu F; Song DQ; Zhen YS
Yao Xue Xue Bao; 2002 Jun; 37(6):405-8. PubMed ID: 12579792
[TBL] [Abstract][Full Text] [Related]
28. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
29. Role of sodium pump systems to determine sensitivity to mitomycin C in non-small cell lung cancer cell lines.
Bando T; Kasahara K; Shibata K; Numata Y; Nakatsumi Y; Fujimura M; Matsuda T
Anticancer Res; 1995; 15(3):769-72. PubMed ID: 7645956
[TBL] [Abstract][Full Text] [Related]
30. [Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity].
Nishiyama M; Saeki S; Aogi K; Hirabayashi N; Toge T
Gan To Kagaku Ryoho; 1993 Jun; 20(8):1037-41. PubMed ID: 7685584
[TBL] [Abstract][Full Text] [Related]
31. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator.
Adams DJ
Cancer Res; 1989 Dec; 49(23):6615-20. PubMed ID: 2819712
[TBL] [Abstract][Full Text] [Related]
32. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.
Gao X; Au JL; Badalament RA; Wientjes MG
Clin Cancer Res; 1998 Jan; 4(1):139-43. PubMed ID: 9516962
[TBL] [Abstract][Full Text] [Related]
33. [Local chemotherapy of bladder carcinoma with mitomycin (author's transl)].
Flüchter SH; Harzmann R; Hlobil H; Erdmann W; Bichler KH
Urologe A; 1982 Jan; 21(1):24-8. PubMed ID: 6805121
[TBL] [Abstract][Full Text] [Related]
34. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH
Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802
[TBL] [Abstract][Full Text] [Related]
35. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
36. [In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
Fujiya S; Yasuda M; Tahira K; Nakabayashi Y; Yoshioka M; Terashima Y; Hatiya S
Gan To Kagaku Ryoho; 1985 May; 12(5):1080-7. PubMed ID: 3922310
[TBL] [Abstract][Full Text] [Related]
37. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells.
Willson JK; Long BH; Chakrabarty S; Brattain DE; Brattain MG
Cancer Res; 1985 Nov; 45(11 Pt 1):5281-6. PubMed ID: 3931904
[TBL] [Abstract][Full Text] [Related]
38. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
39. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Mikami K; Naito M; Tomida A; Yamada M; Sirakusa T; Tsuruo T
Cancer Res; 1996 Jun; 56(12):2823-6. PubMed ID: 8665520
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
Singh SV; Xu BH; Gupta V; Emerson EO; Zaren HA; Jani JP
Cancer Lett; 1995 Aug; 95(1-2):49-56. PubMed ID: 7656243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
